Epizyme Inc (EPZM) : Foresite Capital Management Iii scooped up 35,000 additional shares in Epizyme Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 511,777 shares of Epizyme Inc which is valued at $4,263,102.Epizyme Inc makes up approximately 2.72% of Foresite Capital Management Iii’s portfolio.
Other Hedge Funds, Including , Norges Bank boosted its stake in EPZM in the latest quarter, The investment management firm added 1,236 additional shares and now holds a total of 432,631 shares of Epizyme Inc which is valued at $3,603,816.Tower Research Capital (trc) boosted its stake in EPZM in the latest quarter, The investment management firm added 105 additional shares and now holds a total of 200 shares of Epizyme Inc which is valued at $1,666. Oxford Asset Management added EPZM to its portfolio by purchasing 133,351 company shares during the most recent quarter which is valued at $1,104,146. Epizyme Inc makes up approx 0.04% of Oxford Asset Management’s portfolio. Woodstock Corp added EPZM to its portfolio by purchasing 27,534 company shares during the most recent quarter which is valued at $278,093. Epizyme Inc makes up approx 0.06% of Woodstock Corp’s portfolio.
Epizyme Inc closed down -0.18 points or -2.34% at $7.52 with 2,17,581 shares getting traded on Monday. Post opening the session at $7.77, the shares hit an intraday low of $7.42 and an intraday high of $7.77 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Epizyme Inc. is a clinical-stage biopharmaceutical company that discovers develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases or HMTs. The Company’s lead product candidate EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling and Phase I MLL-r pediatric patient trial enrolling.